(Total Views: 671)
Posted On: 01/23/2024 3:07:59 AM
Post# of 148870
This entry was the first publication for Cytodyn...12 more would follow covering several indications.
Phase 2a Study of the CCR5 Monoclonal Antibody Pro140 administered intravenously to HIV-infected ADULTS...Not monkeys.
Received, modified and accepted 20th July 2010.
As regards to SAFETY; No serious adverse events (AE's) or dose-limiting toxicities were reported.
DISCUSSION
In this Study, Pro140 demonstrated POTENT, RAPID and PROLONGED antiretroviral activity...when it was administered as a single 5-mg/kg or 10-mg/kg intravenous infusion to individuals infected with CCR5-Tropic HIV-1.
Seven authors contributed to the first publication...# 2 was Dr. Jacob P. Lalezari...almost 13 years ago...is there any wonder why he was so pissed at management...contributors to this publication were from Montifiore and Einstein...sounds very familiar.
Phase 2a Study of the CCR5 Monoclonal Antibody Pro140 administered intravenously to HIV-infected ADULTS...Not monkeys.
Received, modified and accepted 20th July 2010.
As regards to SAFETY; No serious adverse events (AE's) or dose-limiting toxicities were reported.
DISCUSSION
In this Study, Pro140 demonstrated POTENT, RAPID and PROLONGED antiretroviral activity...when it was administered as a single 5-mg/kg or 10-mg/kg intravenous infusion to individuals infected with CCR5-Tropic HIV-1.
Seven authors contributed to the first publication...# 2 was Dr. Jacob P. Lalezari...almost 13 years ago...is there any wonder why he was so pissed at management...contributors to this publication were from Montifiore and Einstein...sounds very familiar.
(7)
(0)Scroll down for more posts ▼
